Shui, L., Cheng, K., Li, X., Shui, P., Li, S., Peng, Y., . . . Cao, D. (2020). Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma. Front Immunol.
Style de citation ChicagoShui, Lin, et al. "Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma." Front Immunol 2020.
Style de citation MLAShui, Lin, et al. "Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma." Front Immunol 2020.
Attention : ces citations peuvent ne pas être correctes à 100%.